Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Brachydactyly type A2 (BDA2) is a congenital malformation characterized by shortening (hypoplasia or aplasia) of the middle phalanges of the index finger and, sometimes, of the little finger.
Features include: Short hallux, Short middle phalanx of the 5th finger, 2-3 toe syndactyly, and Triangular shaped middle phalanx of the 5th finger and 10 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Arms and legs | 11 | Short middle phalanx of the 5th finger, 2-3 toe syndactyly, Triangular shaped middle phalanx of the 5th finger |
BMP2 encodes bone morphogenetic protein 2 (396 aa). Growth factor of the TGF-beta superfamily that plays essential roles in many developmental processes, including cardiogenesis, neurogenesis, and osteogenesis. Induces cartilage and bone formation. Highest expression in Lung (24.1 TPM) and Thyroid (18.3 TPM).
Brachydactyly type A2 is associated with mutations in the BMP2 gene on chromosome 20.
The BMP2 protein participates in BMP2:BMP type II receptor:Phospho-BMP type I receptor:I-SMAD pathway.
BMP2 is classified as a druggable target (Cell Surface, Druggable Genome, Growth Factor, and Transcription Factor categories) with score 26.1.
BMPR1B encodes bone morphogenetic protein receptor type 1B (502 aa). On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Highest expression in Nerve Tibial (19.1 TPM) and Prostate (13.7 TPM).
Brachydactyly type A2 is associated with mutations in the BMPR1B gene on chromosome 4.
Genetic testing for BMP2, BMPR1B, GDF5 is available. Testing is considered confirmatory for diagnosis.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for brachydactyly type A2.
3 publications have been identified in PubMed for brachydactyly type A2. Research spans Basic Science / Preclinical (67%) and Review / Meta-Analysis (33%).
Liao J (2026). [PMID: 41530114](https://pubmed.ncbi.nlm.nih.gov/41530114/). *Bone Res*. [Review / Meta-Analysis]
Stavrén-Eriksson E (2025). [PMID: 39970956](https://pubmed.ncbi.nlm.nih.gov/39970956/). *Clin Genet*. [Basic Science / Preclinical]
Songkoomkrong S (2024). [PMID: 39488645](https://pubmed.ncbi.nlm.nih.gov/39488645/). *Sci Rep*. [Basic Science / Preclinical]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 12:48 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
The BMPR1B protein participates in Signaling by BMP and Definitive endoderm cell produces ventral foregut endoderm cell pathways.
BMPR1B is classified as a druggable target (Cell Surface, Druggable Genome, Enzyme, Kinase, and Serine Threonine Kinase categories) with score 6.5.
GDF5 encodes growth differentiation factor 5 (501 aa). Growth factor involved in bone and cartilage formation. During cartilage development regulates differentiation of chondrogenic tissue through two pathways. Highest expression in Cells Cultured fibroblasts (7.0 TPM) and Minor Salivary Gland (4.0 TPM).
Brachydactyly type A2 is associated with mutations in the GDF5 gene on chromosome 20.
The GDF5 protein participates in Signaling by BMP pathway.
GDF5 is classified as a druggable target (Druggable Genome, Growth Factor, and Transcription Factor categories) with score 0.0.